News Hub | News Direct

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

ADIA FATE MESO CRSP

Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer's, the possibilities are vast. While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments. The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine. Now, let's take a closer look at a few stocks making waves in this sector. ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA’s recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector. One of the company's standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country. ADIA’s medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient's blood, is being used to treat a variety of conditions, including Alzheimer’s disease. This is a major move in a rapidly growing field. According to ADIA’s CEO, Larry Powalisz, “Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.” This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases. Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, “We’re crafting a movement for reliability and excellence.” The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry. On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company’s treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA’s international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow. Lastly, ADIA’s asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA’s stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions. ADIA Nutrition’s combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve. Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company's approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective. One of the most promising candidates in Fate’s pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn’t require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate’s President of Research and Development, expressed his excitement over the results, saying, “We are pleased with the early clinical data, which continues to support the potential for disease transformation.” In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly. Fate’s pipeline doesn’t stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers. On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company’s strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential. With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead. Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company's therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others. Mesoblast's FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil. The company is also working on expanding Ryoncil’s applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases. In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications. Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast’s CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, "Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy." Overall, Mesoblast’s strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally. CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company’s flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024. Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a "milestone-rich year" with major clinical updates expected across the company’s pipeline. While CASGEVY’s commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression. CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex’s commercial expertise as they roll out the therapy globally. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 02, 2025 07:00 AM Eastern Daylight Time

Mid-Sized Data Centers Are Winning the Communications Battle While Many Industry Leaders Fall Behind

Hot Paper Lantern

Hot Paper Lantern (HPL), an integrated communications and marketing agency that helps brands build their reputations, create meaningful impact, and generate growth, released its latest data center industry study, "Who's Owning the Conversation?" The study analyzed over 35 companies spanning three key verticals: data center operators, cooling technology vendors, and network service providers. Data Center Operators included in the study: Aligned Data Centers • CloudHQ • Cologix • Compass Datacenters • COPT • CoreSite • DataBank • Digital Core REIT • EdgeConneX • Evoque Data Center Solutions • Flexential • OVHcloud • QTS Data Centers • Sabey Data Centers • STACK Infrastructure • Switch Inc. • Tencent Cloud • Vantage Data Centers Cooling Technology Vendors included in the study: Amana Heating & Air • American Standard • Bryant Heating & Cooling • Goodman Manufacturing • Heil Heating & Cooling • Nortek Global • Rheem • Rudd Heating & Cooling • York Air Conditioning • York International Network Service Providers included in the study: Adtran • Allied Telesis • Calix • Cambium Networks • D-Link • Inseego • MikroTik • TP-Link • Viavi Solutions • Zyxel Communications The research examines how these companies are shaping the mid-market narrative, identifies key areas for improvement, and offers data-driven strategies to help companies drive meaningful engagement. While some organizations take a proactive approach to their external communications by leveraging social media and media relations, others remain passive and allow third parties to shape their company’s narrative. This contrast sparks critical questions about how key sectors engage with their stakeholders and whether or not they will fully capitalize on the opportunities presented by the data center industry's unprecedented growth. "Data center operators have assumed that by just being active to generate some form of media coverage alone, this will translate to having a strong reputation. Our research proves that this is not the case. If you are not actively shaping your own story, someone else will do it for you, and often not in your favor," said Ed Moed, chief executive officer at Hot Paper Lantern. "The data center industry has grown exponentially in recent years, fueled by massive investments, technological advancement, and industry demand. Many companies have relied on that growth to define their value in the market, but as competition increases, a strong and strategic narrative is what will set organizations apart." Key Insights from the Study: Public Perception Doesn't Always Align with Coverage Volume – More coverage does not always translate to a stronger reputation. Nearly 10% of all social media conversations about the data center industry are negative. However, over 80% of that negativity comes from just two companies, and both are among the most active on social media. Their outsized presence has amplified criticism, highlighting the risks of lacking a strategic online narrative. Mid-Tier Operators Punch Above Their Weight in Influence — Despite having smaller budgets, some mid-tier data centers generate outsized impact. Based on revenue, the bottom half of companies analyzed averaged 7x more coverage and 15x more engagement, demonstrating the power of strategic messaging. Cooling Technology Vendors Are Missing Their Storytelling Opportunity — With sustainability and energy efficiency becoming critical topics, cooling providers remain surprisingly underrepresented in industry conversations. Ninety percent of cooling brands generate fewer than 500 media mentions across major platforms, creating a massive opportunity for those willing to participate in the discussion. Network Providers Are Failing to Engage the Data Center Audience — Despite playing a crucial role in data center operations, many network providers struggle to connect with their target audience. Most rely on generic product announcements rather than crafting narratives that will resonate with data center decision-makers. As a result, the top 40% of network providers account for 95% of the industry's digital visibility, leaving the majority with little influence in the conversation. "Cooling and network providers have expanded alongside the data center industry, yet their voice in industry discussions has not kept pace," said Moed. "As artificial intelligence accelerates demand for advanced infrastructure, these sectors must step forward. The companies that fail to establish themselves as industry leaders risk being overlooked, while those that actively shape the conversation will define the next phase of innovation and growth." For more details on the "Who's Owning the Conversation?" study, view the report here. HPL will continue tracking industry trends and key players, releasing quarterly reports about the evolving conversation. To stay informed on the latest findings and updates, visit www.hotpaperlantern.com and sign up for future reports. Hot Paper Lantern (HPL) is a New York City-based integrated communications and marketing agency that helps brands build their reputations, create meaningful impact, and generate growth. HPL partners with clients to find, engage, and form deeper connections with key audiences and stakeholders. For more information, visit www.hotpaperlantern.com. Contact Details Hot Paper Lantern emoed@hotpaperlantern.com Company Website https://hotpaperlantern.com/

April 01, 2025 10:00 AM Eastern Daylight Time

UNOS adds two members to its board of directors

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) announced that its Board of Directors has unanimously approved two new board members, bringing the board complement to nine. Melina Davis and Mark Johnson will begin their terms on April 1, 2025, serving until September 30, 2028. They were approved by a full board vote on March 24. “I’m pleased to welcome Melina and Mark to the UNOS Board of Directors,” said Sue Dunn, chair of the UNOS board of directors. “They each have an incredible background that exemplifies UNOS’ strategic priorities and work to help save and improve lives.” Davis and Johnson bring decades of executive leadership to the UNOS Board of Directors, both within and outside of healthcare. Davis is the CEO and executive vice president of the Medical Society of Viriginia and Johnson is the former CEO of Averhealth and BetterMed Urgent Care. “I’m honored to join the UNOS Board of Directors. UNOS is an organization that’s committed to enhancing the lives and health of individuals. Together, with my fellow board members, I will advocate for innovative solutions, enhance donor awareness, and strive to improve the overall donation and transplant system,” said Davis. “By collaborating, we can advance our goal to give hope and a second chance to many individuals and their families. I look forward to engaging with the community and harnessing our collective expertise to drive meaningful change.” “It’s an honor to be appointed to the UNOS Board of Directors, and for the opportunity to work with UNOS’ CEO Maureen McBride and the UNOS team as they pursue strategic initiatives to provide critical, high-value organ sharing and transplant services,” said Johnson. “As the complex organ transplantation system undergoes change, UNOS’ breadth and depth of know-how, and its extensive relationships with transplant hospitals and other stakeholders, point to a bright future for UNOS and for the many patients who rely on critical organ donations. I look forward to contributing strategic, financial and capital deployment support to UNOS as it advances its mission.” Davis and Johnson join UNOS’ current seven-member board, whose term began on March 30, 2024: Sue Dunn, former CEO of Donor Alliance Bapu Jena, M.D., Ph.D., professor of health care policy at Harvard Medical School, internist at Massachusetts General Hospital Maryl Johnson, M.D., professor at the University of Wisconsin School of Medicine Irene Kim, M.D., director of the Comprehensive Transplant Center at Cedars-Sinai Jake Kouns, founder of RVAsec James Pittman, assistant vice president of transplant and dialysis services for HCA Healthcare Marie Quintero-Johnson, retired vice president of corporate development for Coca-Cola and kidney recipient About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Company Website https://unos.org

March 31, 2025 02:01 PM Eastern Daylight Time

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

Global Markets News

Palatin Technologies* has unveiled compelling topline results from its Phase 2 study showing that patients receiving its obesity drug bremelanotide in combination with tirzepatide achieved a 4.4% weight reduction compared to just 1.6% for placebo—a highly statistically significant difference (p<0.0001). The eight-week trial demonstrated that combining these two mechanisms creates a synergistic effect, with 40% of patients in the combination group achieving at least 5% weight loss compared to 27% with tirzepatide alone. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Perhaps most intriguing for the obesity treatment landscape, Palatin's data revealed that its drug effectively halted the rapid weight regain typically seen after stopping GLP-1/GIP therapy. This addresses one of the most significant challenges facing current obesity treatments, where patients often regain substantial weight after discontinuation. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Palatin is advancing development of next-generation long-acting injectable and oral versions of its obesity compounds, with investigational new drug applications planned for late 2025 and clinical data expected in early 2026. The company is one of just two developing therapies targeting this specific biological pathway for obesity. This announcement follows recent positive news from Palatin's ulcerative colitis program and FDA orphan drug designation for its oral obesity compound for rare genetic obesity disorders, demonstrating the company's momentum across multiple therapeutic areas with significant unmet needs. Subscribe For More Alerts: https://newsletter.page/wallstreetalerts Recent Palatin Technologies News Highlights: Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis *DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms Contact Details Wall Street Wire Market Aerts Desk media.globalmarkets@gmail.com

March 31, 2025 09:19 AM Eastern Daylight Time

Market Alert: Inspira Technology Gains Industry Exposure as FDA-Cleared Technology Showcased at Major Conference

Global Markets News

Market News Alerts Reports: Inspira Technologies (NASDAQ: IINN)* is gaining attention today as their FDA-cleared INSPIRA™ ART100 life-support system is being showcased at the prestigious AmSECT International Conference in San Diego, potentially exposing their technology to hundreds of perfusion professionals. This high-profile exhibition comes at a strategic moment for Inspira, with recent developments showing momentum: The FDA-cleared INSPIRA ART100 system is being prepared for deployment in leading U.S. hospitals Recent clinical studies demonstrated 96% accuracy for their HYLA blood sensor technology The company is advancing development of their flagship INSPIRA ART500 system With the company visionairy approach targeting approximately 20 million ICU patients with acute respiratory failure annually worldwide, Inspira aims to address significant markets: the $5.7B blood gas analyzer market and the $19B mechanical ventilation sector. The company's approach allows patients to remain awake during treatment without ventilators—addressing a need where current solutions face significant challenges. This conference appearance raises Inspira's profile within the perfusion community, potentially supporting their commercialization strategy as they work to introduce their technology to medical institutions. * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published Market News Alerts Research, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Inspira prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Markets News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:28 AM Eastern Daylight Time

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Global Markets News

NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada potential for revenue in canada alone of $100-150 million dollars. PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Market News Alerts Reports -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense is targeting potential approval in Canada by H1 2026. The company estimates peak annual revenue potential of $100-150M USD in the Canadian market. This meeting marks a critical step in NeuroSense's regulatory strategy for PrimeC PrimeC is NeuroSense's lead drug candidate for ALS, a novel extended-release oral formulation combining ciprofloxacin and celecoxib. The drug has demonstrated promising results in clinical trials, including the Phase 2b PARADIGM study, which showed a 36% reduction in disease progression and 43% improvement in survival rates compared to placebo. In December 2024, NeuroSense reported positive FDA feedback on its Phase 3 trial design for PrimeC, with plans to initiate the pivotal study in mid-2025. The company has also announced entering a binding term sheet with a global pharmaceutical company to advance PrimeC's development, which includes substantial upfront payments and funding for the Phase 3 program. This Canadian regulatory development represents a potential pathway to earlier commercialization while the larger Phase 3 program proceeds for global markets. The neurodegenerative disease treatment market has witnessed transformative licensing deals that highlight the immense value of innovative therapies. GlaxoSmithKline's 2021 collaboration with Alector set a remarkable precedent with a $700 million upfront payment and potential milestone payments of $1.5 billion, while the Biogen and Denali Therapeutics partnership in 2020 involved $560 million upfront and potential milestones approaching $1.125 billion. These deals underscore the pharmaceutical industry's willingness to invest heavily in breakthrough neurological innovations, potentially like NeuroSense's PrimeC. Some Wall Street Analysts reportedly maintain a Buy Rating for NeuroSense with AGP giving the company a $7.50 price target representing a significant premium over current Prices; * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution is paid promotional content related to NeuroSense Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by NeuroSense Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details Market News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:01 AM Eastern Daylight Time

Cortland Biomedical Expands Braiding Capabilities with New Flat and Round-Flat-Round Braiders to Drive Medical Device Innovation

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of custom engineering services, has expanded its braiding capabilities with the addition of flat braiding and round-flat-round braiding equipment. This latest investment provides Cortland Biomedical’s OEM customers with access to a full suite of braiding technologies, further strengthening the company’s position as a trusted partner enabling less invasive medical devices across a range of surgical applications. Braids plays a critical role in the design and performance of implantable medical textiles, particularly for orthopedic and sports medicine applications such as tendon and ligament repair. Flat braiding enables precise control over width and thickness, offering enhanced customization for applications requiring flexible yet strong structures that are able to distribute and bear force effectively. Meanwhile, round-flat-round braiding allows for seamless transitions between different braid geometries, optimizing load distribution and mechanical properties essential for next-generation medical devices. This unique structure enables a needle to be attached to the round section or tip, providing additional functionality. “With the addition of these new braiders, we are expanding the design possibilities for our customers, giving them even greater flexibility in developing high-performance biomedical textiles,” said Wesley Conger, engineering director, Cortland Biomedical. “This investment underscores our commitment to delivering custom textile solutions that meet the evolving needs of the medical device industry.” The expanded capabilities complement Cortland Biomedical’s existing expertise in braiding – which already included low and high density braiding, and branch braiding -- as well as woven, knitted, and other advanced textile engineering solutions. By offering a comprehensive range of biomedical textile technologies, the company continues to support OEMs in accelerating innovation and improving patient outcomes. About Cortland Biomedical Cortland Biomedical – which is now FDA registered -- custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

March 19, 2025 10:00 AM Eastern Daylight Time

News Release

Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom

ADIA FATE DNA PLUR

The stem cell and regenerative medicine sector is experiencing a wave of innovation, driven by cutting-edge technologies and an expanding range of applications across healthcare, biotechnology, and even food security. With the potential to revolutionize treatments for conditions like Alzheimer’s, autoimmune disorders, and cancer, stem cell therapies are unlocking new possibilities for regenerative medicine. Advances in iPSC (induced pluripotent stem cells), umbilical cord stem cells, and 3D cell-based platforms are fueling this growth, while increasing demand for affordable and accessible treatments is pushing the market forward. Valued at over $15 billion, the global stem cell market is projected to reach USD 48.83 billion by 2034, registering a CAGR of 11.3% from 2024 to 2034. This remarkable growth reflects the sector’s potential as breakthroughs in research translate into real-world applications. From therapies that harness the body’s own healing mechanisms to scalable solutions addressing global challenges, the opportunities for innovation and investment are immense. Now, let’s explore four stocks making waves in this dynamic and transformative sector. Adia Nutrition Inc. (OTC Pink: ADIA) is making significant strides in the $15.1 billion global stem cell market with its innovative approach to regenerative medicine. The company operates two key divisions: Adia Labs, which provides premium organic supplements, and Adia Med, its medical division specializing in advanced stem cell therapies such as Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT). By focusing on affordability and accessibility, Adia Nutrition is positioning itself as a leader in the rapidly expanding field of regenerative medicine. On March 17, 2025, Adia Med announced that all future full-service clinic locations across the U.S. will offer Therapeutic Plasma Exchange (TPE), a cutting-edge procedure that removes harmful substances from the bloodstream. Already available at the company’s Winter Park, Florida clinic, TPE has shown promise in treating Alzheimer’s disease, autoimmune disorders, and even complications from COVID-19. The treatment utilizes the same advanced apheresis machines used in Hematopoietic Stem Cell Transplantation (HSCT), reinforcing Adia Med’s commitment to leveraging state-of-the-art medical technology. Earlier in March, Adia Labs reached a major milestone with the FDA registration of Adia Vita, its premier stem cell product. Each unit contains 100 million viable cells and 3 trillion exosomes, offering a powerful and cost-effective solution in regenerative medicine. This FDA registration enables Adia Labs to distribute Adia Vita nationwide, expanding access to cutting-edge stem cell therapies for doctors and clinics across the country. With traditional stem cell treatments often costing between $15,000 and $35,000 per procedure, Adia Med stands out by offering high-quality therapies at more affordable rates, fueling rapid client growth. Adia Nutrition’s growth trajectory in 2025 has been marked by several key corporate advancements. In February, the company took steps to strengthen its financial and operational foundation by retiring 25 million undocumented shares, successfully removing its shell risk designation, and launching Adia Labs LLC. These strategic moves not only reinforce investor confidence but also set the stage for an OTCQB uplisting, which will enhance the company’s market visibility and liquidity. To accelerate its expansion, Adia Med is forming partnerships with elite Medical Spas, establishing satellite locations that provide a scalable and low-risk model for nationwide growth. With over 4.5 million Florida residents aged 65 and older, Adia Med is uniquely positioned to address a significant demand for age-related treatments, particularly for conditions like Alzheimer’s and autoimmune disorders. With the expansion of TPE, the nationwide rollout of Adia Vita, and the impending OTCQB uplisting, ADIA is entering a phase of rapid growth. As Adia Nutrition Inc. (OTC: ADIA) continues to scale operations and push the boundaries of regenerative medicine, it is well-positioned to deliver innovative healthcare solutions while generating value for investors, making it a stock to keep an eye on. Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company specializing in iPSC-derived cellular immunotherapies. The company’s proprietary platform creates engineered iPSC lines for off-the-shelf T-cell and NK-cell products, targeting diseases in autoimmunity and oncology. Fate’s lead program, FT819, is an iPSC-derived CAR T-cell therapy for systemic lupus erythematosus (SLE), now in Phase 1 trials. Recent dose-expansion data from SLE patients show promising results, including no significant toxicities and one patient achieving clinical remission. The company is also exploring FT819’s potential in other autoimmune diseases. Fate’s FT825 CAR T-cell therapy targets solid tumors and is being tested in combination with monoclonal antibodies in collaboration with Ono Pharmaceutical. Early data show favorable safety and cellular activity. The company’s FT522 CAR NK cell therapy for B-cell lymphoma is progressing, with the added advantage of not requiring conditioning chemotherapy, thanks to its Alloimmune Defense Receptor (ADR) technology. FT522 is also being evaluated for autoimmune conditions. With $307 million in cash, Fate is well-funded through 2026, allowing it to advance these promising therapies. As the company pushes forward in clinical trials, Fate Therapeutics stands out in the growing field of off-the-shelf stem cell-based treatments with significant growth potential. Ginkgo Bioworks (NYSE: DNA) is a leading cell programming platform, offering end-to-end solutions across industries like food, agriculture, pharmaceuticals, and biosecurity. Their biosecurity division focuses on next-generation infrastructure to help detect and respond to biological threats. In Q4 2024, Ginkgo reported total revenue of $44 million, up 26% from the previous year. This growth was driven by a 29% increase in cell engineering revenue, which reached $35 million. Biosecurity revenue grew modestly to $9 million, reflecting an evolving business model. For the full year, Ginkgo posted $227 million in revenue, down 10% due to the transition in their biosecurity business and a shift in focus toward larger customers in cell engineering. Despite the dip in overall revenue, Ginkgo reduced its GAAP net loss significantly, reporting $547 million, compared to $893 million in 2023. Their adjusted EBITDA loss also improved, dropping from $365 million to $293 million. The company ended 2024 with $562 million in cash, positioning them well to execute their strategy. Strategically, Ginkgo has made notable strides in cell engineering, with 31 new customer programs added in Q4 2024. They also signed a key contract with a top biopharmaceutical company for their antibody developability product. Their Ginkgcellutomation division was selected for a $9.4 million project with Carnegie Mellon to develop bioelectronic devices. Looking ahead, Ginkgo aims to reach adjusted EBITDA breakeven by 2026 and has targeted $250 million in cost reductions by Q3 2025. For 2025, Ginkgo projects $160-$180 million in total revenue, with $110-$130 million expected from Cell Engineering and at least $50 million from Biosecurity. With a strong cash position and clear cost-cutting initiatives, Ginkgo is poised for sustainable growth, particularly in its core cell engineering and biosecurity sectors. Pluri Inc. (Nasdaq: PLUR) stands out in the crowded biotech and stem cell sectors due to its innovative approach to leveraging its proprietary 3D cell-based technology platform. Unlike many other companies that primarily focus on regenerative medicine, Pluri is expanding its impact into areas like foodtech and agtech, making it a versatile and dynamic player. Its cutting-edge technology addresses a wide range of global challenges, from medical advancements to food security and sustainability. By offering scalable, cost-effective, and consistent cell production, Pluri is positioning itself as a leader in creating next-generation solutions for some of the world’s most pressing issues. What really sets Pluri apart is its unique capability to apply its cell-based technology across diverse industries. For example, the company is taking a significant leap into the food industry by partnering with Kokomodo Ltd., an AgTech company focused on cultivated cacao. This move aligns Pluri with the rapidly growing demand for sustainable food production and plant-based alternatives. By acquiring a 71% stake in Kokomodo, Pluri is expanding its reach into the cultivated cacao market, which is expected to grow significantly in the coming years. The deal not only positions Pluri to tap into the billion-dollar cacao market but also showcases its ability to diversify into unconventional applications for cell-based technologies. Moreover, Pluri is expanding its role in global crisis response through its collaboration with Hemafund Ltd. to address the potential need for countermeasures against radiation exposure in Ukraine. The collaboration aims to produce and stockpile PLX-R18, a cell therapy designed to treat Hematopoietic Acute Radiation Syndrome (H-ARS), which could be crucial in the event of nuclear threats. This kind of forward-thinking approach, combining biotech innovation with real-world emergency preparedness, shows Pluri's broader vision for applying its technology to urgent global health needs, making it more than just another biotech company in a competitive market. The company’s recent $6.5 million investment and acquisition announcements reinforce its commitment to growth and innovation. These moves position Pluri not only as a major player in regenerative medicine and cell-based therapies but as a company with the flexibility and vision to push the boundaries of what biotech can achieve across different sectors. By aligning itself with other industries, such as food production and emergency preparedness, Pluri has shown that it is not just riding trends in the biotech space, but rather, shaping the future of multiple industries with its versatile, scalable technologies. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

March 18, 2025 07:00 AM Eastern Daylight Time

Centre For Neuro Skills to Open Clinic in Plano; Fifth in Texas

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, today announced the opening of its new clinic in Plano, Texas. CNS’ approximately 20,000 square ft. facility at 1649 Dallas Parkway will open to new patients in winter 2025-2026. “Over the past few years, we’ve seen population growth in the North Dallas area, with Plano being one of the fastest growing regions,” said David Harrington, CEO of CNS. “We are increasing our footprint in Texas to meet the high demand for our facilities and individualized services to bring high-quality post-acute care to not only North Texas but also neighboring states like Oklahoma.” Patient-centered approach to treating brain injury CNS, highly regarded for its expertise in brain injury and stroke treatment as well as its experienced staff. Three of CNS’ clinics, including one in Irving, recently received accreditation by the Behavioral Health Center of Excellence for demonstrating its commitment to the standards of excellence for applied behavior analysis services. As CNS’ fifth Texas location, the Plano clinic will deepen the post-acute care provider’s commitment to the Dallas Healthcare community and the state. CNS’ Plano location’s many advanced-care features include: Programs for vision, neurobehavior, cognitive retraining, speech, physical and occupational therapy provided by highly trained and certified clinical therapy staff The ZeroG® Gait and Balance System Bioness Integrated Therapy System (BITS), used to aid in vision, motor and balance training Individualized counseling as well as family counseling (a hallmark of CNS support) Opportunities to participate in cutting edge brain injury and stroke research Brain injury and its devastating and costly effects Traumatic brain injury (TBI) is caused by blunt, traumatic forces to the brain. Acquired Brain Injury (ABI) is a non-traumatic brain injury or disease such as stroke, encephalitis or other infectious diseases, anoxic/hypoxic injury (lack of oxygen to the brain), aneurysms, seizure disorders, surgical procedures and toxic exposure. According to the Brain Injury Association of America, 2.9 million Americans visit the emergency department due to a TBI every year. According to the Texas Brain Injury Alliance: 144,000 Texans sustain a TBI each year — one every 4 minutes More than 381,000 Texans live with a disability due to a TBI — 2% of the population More than 5,700 Texas residents are permanently disabled by TBI each year Convenient Location CNS’ new clinic offers space to accommodate a broader population of inpatient, outpatient, day treatment and residential post-acute brain injury patients. It is adjacent to the Dallas North Tollway and located minutes from area airports and hotels. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 13, 2025 08:01 AM Pacific Daylight Time